North Central Neurology Associates, P.C.
Past Clinical Trials
Vaccinex: A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single=Dose Study of the Safety, Tolerability and Pharmacokinetics of Intravenous XXXX in Patients with Multiple Sclerosis. Closed to enrollment.
Biogen Idec: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of XXXX in Subjects with Relapsing Forms of Multiple Sclerosis When Used Concurrently with Avonex. Closed to enrollment.
Novartis: A 12-Month, Prospective, Randomized, active-controlled, open-label study to evaluate patient retention of XXXX vs. approved first-line disease modifying therapies in adults with relapsing remitting multiple sclerosis. Closed to enrollment.
Novartis: A 12-month, randomized, rater and dose-blinded study to compare the efficacy and safety of XXXX 0.25mg and 0.5mg administered orally once daily with XXXX 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis. Closed to enrollment.
Genzyme, A Sanofi Company: A Phase 2a/2b double-blind, randomized, placebo-controlled study assessing efficacy, safety, and dose-response of XXXX in patients with relapsing-remitting multiple sclerosis (RRMS). Closed to enrollment.
Novartis: A multicenter, retrospective, observational study evaluating real-world clinical outcomes in relapsing-remitting multiple sclerosis patients who transition from XXXX to Gilenya.
Biogen Idec: A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release XXXX 10mg, Administered Twice Daily in Subjects with Multiple Sclerosis. Closed to enrollment.
Genzyme, A Sanofi Company: An Extension Protocol for the Multiple Sclerosis Patients Who Participated in Genzyme Sponsored Studies of XXXX. Closed to enrollment.
Genzyme, A Sanofi Company: A long-term follow-up study for Multiple Sclerosis patients who have completed the XXXX Extension Study. Closed to enrollment.
Teva: A Multinational, Multi-center, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Subcutaneous Injections of XXXX 40mg/mL Three Times a Week Compared to 20mg/mL Daily. Closed to enrollment.
EMD Serono: A phase IV, randomized, prospective, US-based, multi-center, cross-over study evaluating subject's ease-of-use with XXX, XXX, and XXX autoinjectors in subjects with relapse remitting multiple sclerosis (RRMS) treated with XXXX 44mcg subcutaneously three times a week. Closed to enrollment.
Genzyme, A Sanofi Company:A prospective observational cohort study in adult patients with relapsing multiple sclerosis to assess patient safety during and after LEMTRADA (alemtuzumab) infusions of the first treatment course. Closed to enrollment.